Pioglitazone for diabetes prevention in impaired glucose tolerance.

By Ralph DeFronzo, D. Tripathy, D. Schwenke, M. Banerji, G. Bray, T. Buchanan, S. Clement, R. Henry, H. Hodis, A. Kitabchi and 7 more. New England Journal of Medicine, 2011

716 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Type 2 diabetes mellitus (2015, background): “has received research support from California Walnut Commission and Metegenics; (11) G.”
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus (2016, positive): “Pioglitazone halts the progression from prediabetes to diabetes (37).”
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. (2016, background): “In clinical trials, thiazolidinediones (TZDs) prevented future development of diabetes in 60 to 75% of subjects with prediabetes, but this class of drugs has been associated with a number of adverse outcomes (67-69).”
PATHOPHYSIOLOGY AND TREATMENT OF TYPE 2 DIABETES: PERSPECTIVES ON THE PAST, PRESENT AND FUTURE (2013, background): “Insulin resistance is already well established if impaired glucose tolerance is present; Lancet 2014; 383: 1068–83 Published Online December 4, 2013 http://dx.doi.org/10.1016/ S0140-6736(13)62154-6 See Online/Comment http://dx.doi.org/10.1016/ S2213-8587(13)70187-6 Division of Metabolism, Endocrinol”